Get the latest Science News and Discoveries
ECOG-ACRIN completes first trial of Black patients with early-stage breast cancer - EurekAlert
Black patients with early-stage breast cancer who were treated with docetaxel chemotherapy every 3 weeks had less drug-induced peripheral neuropathy and significantly fewer dose reductions compared to those who received weekly paclitaxel, according to a trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). Study EAZ171 is the first National Cancer Institute (NCI)-sponsored trial to focus specifically on enrolling a minority or underserved population to assess drug-induced toxicity (rather than drug efficacy) where there are known disparate outcomes.
None
Or read this on Eureka Alert